Booth Andrew 4
4 · AbCellera Biologics Inc. · Filed Jun 9, 2021
Insider Transaction Report
Form 4
Booth Andrew
Chief Financial Officer
Transactions
- Exercise/Conversion
Share Option (right to buy)
2021-06-07−600,000→ 300,000 totalExercise: $0.19Exp: 2026-06-15→ Common Shares (600,000 underlying) - Exercise/Conversion
Common Shares
2021-06-07$0.32/sh+600,000$192,000→ 1,200,000 total - Exercise/Conversion
Common Shares
2021-06-07$0.19/sh+600,000$114,000→ 600,000 total - Exercise/Conversion
Share Option (right to buy)
2021-06-07−600,000→ 4,950,000 totalExercise: $0.32Exp: 2029-08-22→ Common Shares (600,000 underlying)
Holdings
- 116,959(indirect: By Spouse)
Common Shares
Footnotes (2)
- [F1]The shares subject to such option vest and become exercisable annually in equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.
- [F2]2,000,000 shares subject to the option vested and became exercisable on March 23, 2020. The remaining 3,550,000 shares (the "Remaining Shares") subject to the option vest and become exercisable as follows: 25% of the Remaining Shares subject to such option vested and became exercisable on August 22, 2020 and the remainder of the Remaining Shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.